Overcoming Resistance Without the Risk of Reaction: Use of Afatinib and Panitumumab in Two Cases of Epidermal Growth Factor Receptor--Mutated Non--Small-Cell Lung Cancer With T790M Mutations.

Authors	Emily H Castellanos, Gabriel Rivera, Heather Wakelee, Leora Horn
Journal	Clinical lung cancer (Clin Lung Cancer) Vol. 16 Issue 5 Pg. e97-9 (Sep 2015) ISSN: 1938-0690 [Electronic] United States
PMID	25842367 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References	Antibodies, Monoclonal Quinazolines Afatinib Panitumumab EGFR protein, human ErbB Receptors
Topics	Afatinib Aged Antibodies, Monoclonal (administration & dosage) Antineoplastic Combined Chemotherapy Protocols (therapeutic use) Carcinoma, Non-Small-Cell Lung (drug therapy, genetics, pathology) Drug Resistance, Neoplasm ErbB Receptors (genetics) Female Humans Lung Neoplasms (drug therapy, genetics, pathology) Middle Aged Mutation Panitumumab Quinazolines (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!